A Phase 1, multicenter, open-label, dose escalation and

Project: Research project

Description

A Phase 1, multicenter, open-label, dose escalation and expansion study to evaluate the safety, tolerability, and pharmacokinetics of MEDI0639 as a single-agent or in combination therapy in adult subject
StatusFinished
Effective start/end date3/10/143/30/19

Funding

  • MedImmune, LLC

Fingerprint

Pharmacokinetics
Safety
Therapeutics